Electrophysiology of Brain Activity During Electrode Implantation in Patients Treated With Deep Brain Stimulation
NCT ID: NCT03874611
Last Updated: 2019-03-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
125 participants
INTERVENTIONAL
2011-04-13
2021-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Demonstrate functional markers derived from electrophysiological signals recorded during cognitive tests. These markers should make it possible to optimize the targeting procedures of electrode implantation sites for a better effectiveness of deep brain stimulation therapy.
Research hypotheses
The mechanisms of action of the deep brain stimulation (DBS) involve the modulation of the activity, locally and on a large scale, of functional cortical-subcortical networks showing pathological behavior beforehand. The electrophysiological measurements in response to different tasks make it possible to highlight precise dysfunctions of these neural networks, in relation with the behavioral and / or motor disorders associated with the pathologies treated by DBS.
Consequently, we hypothesize that the exploitation of electrophysiological responses during cognitive or sensorimotor tasks performed during the implantation procedure of stimulation electrodes in patients treated with DBS will allow :
* To collect fundamental data to understanding the physiological functioning of basal ganglia in humans ;
* To collect functional markers from the operating room in relation to the symptoms targeted by the DBS that will help in the choice of implantation site of the stimulation electrode ;
* Define long-term predictive markers of DBS effects by comparing electrophysiological effects measured post-operatively and clinical scores under DBS.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Electroencephalographic Monitoring in Patients Treated by Deep Brain Stimulation
NCT03114748
Determination of Biomarkers of the Effectiveness of Deep Brain Stimulation by Direct Electrophysiological Recordings of Brain Activity in a Cognitive Context - LFP-DBS 2024
NCT06813300
ON/OFF Stimulation and Reward Motivation in Patients With Deep Brain Stimulators
NCT01590862
Long Term Follow-up of Hippocampal DBS for Refractory Epilepsy
NCT03404128
Prediction of the Cognitive Effects of Electroconvulsive Therapy Via Machine Learning and Neuroimaging
NCT03490149
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
electrophysiological data from DBS
electrophysiological data from DBS
For each selected patient, the evaluation of cognitive or sensory-motor functions by electrophysiology will be conducted in the operating room, preoperatively the week before implantation and post-operatively within five days between the implantation of deep electrodes and the setting of the stimulator.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
electrophysiological data from DBS
For each selected patient, the evaluation of cognitive or sensory-motor functions by electrophysiology will be conducted in the operating room, preoperatively the week before implantation and post-operatively within five days between the implantation of deep electrodes and the setting of the stimulator.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients aged 18 to 75 and affiliated to a social security scheme
* Idiopathic Parkinson's disease that meets the United Kingdom Parkinson's Disease Brain Bank (UKPDSBB) criteria or suffering from recessive autosomal juvenile parkinsonism
* duration of evolution of the disease\> 5 years
* stage of severe motor complications of levodopa despite optimal treatment.
* Disabling dystonia (severe focal, segmental or generalized).
* Patient ≥ 18 years of age and under age 65
* Duration of evolution of dystonia greater than one year.
* OCD which has been diagnosed for at least 5 years according to the DSM-IV criteria as OCD with "good insight", confirmed using the Diagnostic Interview Genetic Study (DIGS) - OCD section ; score below the delusional idea threshold at the BABS (Brown Assessment of Beliefs Scale) insight scale (Eisen, Phillips et al., 1998)
* OCD of severe intensity (total YBOCS \> 25, or subscale Obsessions or Compulsions \> 15, EGF \< 40, CGI \> 4) with prognosis considered to be bad in the absence of intervention
* Non-responder OCD (an improvement of less than 25% on the Y-BOCS scale) to at least three IRS-type antidepressants, including clomipramine, used sequentially at the maximum tolerated dose for at least 12 weeks. Used alone and in combination for at least 1 month with risperidone or pimozide and any of the following products : lithium salts or clonazepam or buspirone or pindolol (Greist and Jefferson 1998) (McDougle, Epperson et al 2000) (Dannon , Sasson et al., 2000)
* OCD having benefited from Behavioral and Cognitive Therapy for at least 1 year (application of classical programs, including exposure techniques with prevention of ritualized response, with at least two sessions per month).
* Patient between 18 and 60 years of age who has given his signature and informed consent after receiving written information on the proposed procedure
* Sick with social security
* male or female between the ages of 30 and 65
* with a diagnosis of unipolar major depression (MINI) resistant to conventional treatments
* Hamilton and Montgomery Depression Scale (HAMD) score\> 20
* Duration of the current depressive episode of more than 12 months, the patient being included in a care system has established the chronic and recurrent state of this depression,
* Ineffective treatment of the current episode with at least 4 therapeutic attempts including antidepressant drug monotherapy treatments (MAOIs, tricyclic antidepressants, selective serotonin reuptake inhibitors, mixed serotonin reuptake inhibitors, and norepinephrine), the potentiations of antidepressant treatments (by lithium salts, thyroid hormones or neuroleptics), the psychotherapies structured according to validated techniques, the ECT carried out under conditions in conformity with the recommendations (ANAES, 1998) (at least 6 sessions in technical bilateral with control of duration of seizure)
* Women of childbearing age should follow a contraceptive method that is considered sufficiently effective by the investigator. In this case a pregnancy test will be performed on inclusion
* outpatient or inpatient
* fluent in the French language and able to understand the procedures of the study and in particular complete the self-questionnaires used
* Patient likely to give informed consent
* Patient affiliated with Social Security
* Patient's written agreement to participate in the study
* Intellectual abilities compatible with cognitive or motor tasks
Exclusion Criteria
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Grenoble
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Grenoble-Alpes
Grenoble, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Stephan CHABARDES, Pr
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
38RC11.242
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.